Read highlights from the latest installment of Dusko Ilic’s industry news, which discuss the latest developments and news in regenerative medicine and stem cell research, and are published every month in Regenerative Medicine.
Every month, Dusko comments on regenerative medicine industry news of note. Read the full update for June 2021 in Regenerative Medicine here >>>
What happened this month that you were expecting?
MIMEDX Group (GA, USA), a Company utilizing amniotic tissue as a platform for regenerative medicine, has published a study demonstrating potential for processed dehydrated amnion/chorion membrane (dHACM) to modulate pathological scar tissue formation, exploring the potential mechanism of action. The healing potential of amniotic membrane preparations and reduced scaring following the treatment has been observed for many years. It is about time that someone seriously dug into the issue and found out how HAM/HACM affects fibrotic pathways. Good start!
What happened that surprised you this month?
Launching a new CAR-T therapy
The chimeric antigen receptor (CAR) T-cell business is still booming, and investors are closely monitoring the field looking for an opportunity to invest and make a profit. Blackstone Group (NY, USA), a private investment platform, has committed USD$250 million towards the launch of a new autologous and allogeneic universal CAR-T therapy company, along with Intellia Therapeutics (MA, USA) and Cellex Cell Professionals (Köln, Germany), the parent company of clinical-stage cell therapy company GEMoaB (Dresden, Germany). How long will this be going on? No end in sight to this heat wave.
If we only read about one story this month, what should it be?
Unproven stem cell interventions: a global public health problem
Despite efforts to tackle the issue, the unproven stem cell intervention industry continues to flourish. In the June issue of Stem Cell Reports, three USA-based experts call for a global approach and the establishment of a World Health Organization (WHO) Expert Advisory Committee on Regenerative Medicine to address this issue and provide guidance.
Dr Dusko Ilic
Dusko Ilic is a Senior Lecturer in stem cell science, coordinator of the cross-divisional postgraduate program in stem cells and regenerative medicine, and Head of the Induced Pluripotent Stem Cell Core Facility at King’s College London (London, UK). He is also Head of the Assisted Conception Unit’s Human Embryonic Laboratories at Guy’s Hospital (London, UK). He is also a member of the editorial board of the journal Regenerative Medicine, where he writes the Industry Report, a regular feature compiling information from non-academic institutions in the field of stem cells and regenerative medicine.